Skip to main content

Table 1 PARPi compounds in clinical development

From: PARP inhibitors in the management of breast cancer: current data and future prospects

Drug name

Pharmaceutical company

Current investigational phase in breast cancer

Olaparib (AZD2281)

AstraZeneca

Phase 3 studies in adjuvant and advanced settings in germline BRCAm breast cancer

Veliparib (ABT-888)

Abbvie

Phase 3 study in neoadjuvant setting in combination with carboplatin and standard therapy in triple-negative breast cancer

Phase 2/3 studies in advanced setting as combination therapy in germline BRCAm breast cancer

Niraparib (formerly MK-4827)

Tesaro

Phase 3 study in advanced setting in germline BRCAm breast cancer

Talazoparib (BMN-673)

BioMarin Pharmaceuticals

Phase 3 study in advanced setting in germline BRCAm breast cancer

Phase 2 studies in advanced setting in BRCAm breast cancer

Phase 2 study in advanced setting in germline BRCA intact breast cancer

Phase 2 study in neoadjuvant setting in BRCAm breast cancer

Rucaparib (formerly AG-14699)

Clovis Oncology

Phase 2 study in advanced setting in patients with known germline BRCAm solid tumors

Phase 2 study in adjuvant setting in triple-negative breast cancer or germline BRCAm breast cancer

CEP-9722

Teva Pharmaceutical Industries

Phase 2 study in advanced setting in solid tumors

  1. BRCAm, BRCA1/2 mutation-associated